Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials
Authors' conclusion
A robust dose-response relationship between bodyweight loss and diabetes remission was observed, independent of age, diabetes duration, HbA1c, BMI, and type of intervention. These findings highlight the crucial role of bodyweight loss in managing type 2 diabetes and reducing the risk of diabetes-related complications.
Study context
- Population
- Individuals with T2D and overweight or obesity in RCTs22 publications
- Comparison
- Categories of bodyweight loss and T2D remission
- Outcome
- Proportion with complete remission (HbA1c <6.0% or FPG <100 mg/dL, or both, no glucose-lowering drugs) or partial remission (HbA1c <6.5% or FPG <126 mg/dL, or both, no glucose-lowering drugs)
- Follow-up
- At least 1 year after intervention
Methodological detailsCochrane and PRISMA guidelines, Data from RCTs with low risk of bias in all quality domains
- Cochrane and PRISMA guidelines
- Data from RCTs with low risk of bias in all quality domains
Pooled result
As reported in the abstract
Complete remission (pooled mean proportion) · 1 year after intervention
- Increase in probability of complete remission per 1 percentage point decrease in bodyweight
- 2.17 percentage points (95% CI 1.94-2.40)
Further pooled results
Pooled mean
| Outcome | <10% | 10-19% | 20-29% | ≥30% |
|---|---|---|---|---|
| Partial remission (pooled mean proportion) · 1 year after intervention | 5.4% (95% CI 2.9–8.4) | 48.4% (CI 36.1–60.8) | 69.3% (CI 55.8–81.3) | 89.5% (CI 80.0–96.6) |
- Partial remission (pooled mean proportion) — Increase in probability of partial remission per 1 percentage point decrease in bodyweight
- 2.74 percentage points (2.48-3.00)
Other factors and remission
- No significant or appreciable associations between age, sex, race, diabetes duration, baseline BMI, HbA1c, insulin use, or type of intervention and remission
Original publication
Impact of bodyweight loss on type 2 diabetes remission: a systematic review and meta-regression analysis of randomised controlled trials. Lancet Diabetes Endocrinol. Published 26 February 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →